---
url: https://www.servicesaustralia.gov.au/lymphoma-t-cell-lymphoma
title: Lymphoma - T-cell lymphoma - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:09.590Z
source: servicesaustralia.gov.au
---
# Lymphoma - T-cell lymphoma

The PBS subsidises brentuximab vedotin or vorinostat for patients with cutaneous T-cell lymphoma (CTCL), and brentuximab vedotin for patients with peripheral T-cell lymphoma (PTCL).

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 arrangements](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with brentuximab vedotin under the _National Health Act 1953_, section 100 for patients with CTCL and PTCL.

The PBS subsidises treatment with vorinostat under the _National Health Act 1953_ section 85 for patients with CTCL.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines restrictions for prescribing brentuximab vedotin or vorinostat.

## Section 100 arrangements

### Brentuximab vedotin

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

-   an approved private hospital
-   a public participating hospital.

This item isn’t PBS-subsidised for public hospital in-patients.

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised brentuximab vedotin or vorinostat to treat CTCL or PTCL can be made either in:

-   real time using the [Online PBS Authority system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include the completed:

-   authority prescription form or forms
-   relevant initial authority application form
-   relevant attachments.

Select the authority application form relevant to the condition treated and the medication being prescribed:

-   [cutaneous T-cell lymphoma (CTCL) - brentuximab vedotin - initial authority application form](/pb268?context=20)
-   [cutaneous T-cell lymphoma (CTCL) - vorinostat - initial authority application form](/pb216?context=20)
-   [peripheral T-cell lymphoma (PTCL) - brentuximab vedotin - initial authority application form](/pb314?context=20).

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised brentuximab vedotin or vorinostat to treat CTCL or PTCL can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drug Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs) enquiry line for more information.
